Heron Therapeutics, Inc. (HRTX) Forms $29.85 Double Top; Ribbon Communications (RBBN) Shorts Increased By 39.62%

April 12, 2018 - By Jerrie Dane

Heron Therapeutics, Inc. (HRTX) formed double top with $32.24 target or 8.00% above today’s $29.85 share price. Heron Therapeutics, Inc. (HRTX) has $2.11B valuation. The stock increased 1.53% or $0.45 during the last trading session, reaching $29.85. About 282,640 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 87.03% since April 12, 2017 and is uptrending. It has outperformed by 75.48% the S&P500.

Ribbon Communications Inc (NASDAQ:RBBN) had an increase of 39.62% in short interest. RBBN’s SI was 2.19 million shares in April as released by FINRA. Its up 39.62% from 1.57 million shares previously. With 354,900 avg volume, 6 days are for Ribbon Communications Inc (NASDAQ:RBBN)’s short sellers to cover RBBN’s short positions. The SI to Ribbon Communications Inc’s float is 4.54%. The stock increased 1.34% or $0.07 during the last trading session, reaching $5.28. About 49,367 shares traded. Ribbon Communications Inc. (NASDAQ:RBBN) has declined 20.88% since April 12, 2017 and is downtrending. It has underperformed by 32.43% the S&P500.

Among 15 analysts covering Heron Therapeutics (NASDAQ:HRTX), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics has $58 highest and $22 lowest target. $41.57’s average target is 39.26% above currents $29.85 stock price. Heron Therapeutics had 42 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Aegis Capital on Wednesday, October 26. The rating was maintained by Cowen & Co on Friday, May 26 with “Buy”. Bank of America initiated the stock with “Buy” rating in Wednesday, September 2 report. On Wednesday, January 31 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $31.0 target in Tuesday, February 27 report. The rating was maintained by Oppenheimer on Monday, March 19 with “Buy”. Oppenheimer maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) on Tuesday, March 27 with “Buy” rating. The firm has “Buy” rating by Lake Street given on Thursday, April 5. Cantor Fitzgerald maintained the shares of HRTX in report on Friday, August 18 with “Buy” rating. The firm has “Buy” rating by Needham given on Monday, March 19.

Analysts await Heron Therapeutics, Inc. (NASDAQ:HRTX) to report earnings on May, 9. They expect $-0.85 earnings per share, up 15.00% or $0.15 from last year’s $-1 per share. After $-1.09 actual earnings per share reported by Heron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -22.02% EPS growth.

Ribbon Communications Inc. provides networked solutions worldwide. The company has market cap of $538.19 million. The firm offers Session Border Controllers that address security and interworking requirements for businesses, as well as regional and global communications service providers; Sonus GSX9000 Open Services Switch, which bridges IP and TDM networks by converting voice signal into Internet Protocol (IP) IP packets and transmitting those IP packets on a data network; and Sonus T7000 Intelligent Switching System, a class five end-office soft switch that provides residential and business voice services, as well as IP-IP multimedia processing engine services. It currently has negative earnings. It also provides Diameter Signaling Controller, a solution for 4G/long term evolution networks; Sonus Signal Transfer Point that acts as the switch/router in an SS7 signaling network; Sonus PSX Policy & Routing Server, a central routing and policy engine for its soft switch and distributed SBC solutions; and Web Real-Time Communications services solution.

Ribbon Communications Inc. (NASDAQ:RBBN) Ratings Chart